Skip to content

Study · Other design · 2025

3 results

Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.

Gofron KK, Wasilewski A, Małgorzewicz S

Nutrients9 Apr 2025Cited by 72 (Europe PMC)

PMID40284168 (opens in a new tab)PMCIDPMC12029897 (opens in a new tab)DOI10.3390/nu17081303 (opens in a new tab)PepBankPUB-40284168
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundGLP-1 analogues are a relatively new class of medications that form the cornerstone of diabetes treatment. They possess invaluable glucose-lowering properties without hypoglycemic effects as well as strong cardioprotective effects. The gut microbiome has become the focus of numerous studies, demonstrating its influence not only on the gut but also on the overall well-being of the entire body. However, the effects of GLP-1 analogs on gut microbiota remain uncertain.Scope of reviewOur systematic review (based on PRISMA guidelines) aimed to gather knowledge on the effects of GLP-1 analogue medications on the composition, richness, and abundance of gut microbiota in both animal and human models.ConclusionsThirty-eight studies were included in this systematic review. GLP-1 analogues have demonstrated a notable impact on the composition, richness, and diversity of gut microbiota. We can conclude, following the obtained research results of our study, that liraglutide promotes the growth of beneficial genera relevant for beneficial metabolic functions. Exenatide and exendin-4 administration showed various effects on the microbiome composition in animal and human studies. In animal models, it increased genera associated with improved metabolism; however, in human models, genera linked to better metabolic functions and escalated inflammation increased. Following dulaglutide administration, increases in Bacteroides, Akkermansia, and Ruminococcus, genera connected to an improved metabolic model, were significant. Finally, varied results were obtained after semaglutide treatment, in which A. muciniphila, known for its positive metabolic functions, increased; however, microbial diversity decreased. Semaglutide treatment provided various results indicating many confounding factors in semaglutide's impact on the gut microbiota. Results varied due to dissimilarities in the studied populations and the duration of the studies. Further research is essential to confirm these findings and to better recognize their implications for the clinical outcomes of patients.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalOther designEfficacy outcome

    In a systematic review of animal and human models, liraglutide promoted growth of beneficial gut genera relevant to metabolic functions; the native result was not separated by animal/human model and its comparator and analyzed N were unstated.

    In plain wordsIn animal and human research reviewed together, liraglutide increased beneficial gut bacteria; the specific model and comparison were unstated.

    Peptide
    Liraglutide
    Outcome
    IncreaseGrowth of beneficial gut genera
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We can conclude, following the obtained research results of our study, that liraglutide promotes the growth of beneficial genera relevant for beneficial metabolic functions.
    2 context sentences
    Summary · context
    Our systematic review (based on PRISMA guidelines) aimed to gather knowledge on the effects of GLP-1 analogue medications on the composition, richness, and abundance of gut microbiota in both animal and human models.
    Summary · context
    Thirty-eight studies were included in this systematic review.
  2. 02AnimalOther designEfficacy outcome

    In a systematic review of animal and human models, semaglutide treatment increased A. muciniphila; the native result was not separated by animal/human model and its comparator and analyzed N were unstated.

    In plain wordsIn animal and human research reviewed together, semaglutide increased A. muciniphila; the specific model and comparison were unstated.

    Peptide
    Semaglutide
    Outcome
    IncreaseA. muciniphila abundance
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, varied results were obtained after semaglutide treatment, in which A. muciniphila, known for its positive metabolic functions, increased; however, microbial diversity decreased.
    2 context sentences
    Summary · context
    Our systematic review (based on PRISMA guidelines) aimed to gather knowledge on the effects of GLP-1 analogue medications on the composition, richness, and abundance of gut microbiota in both animal and human models.
    Summary · context
    Thirty-eight studies were included in this systematic review.
  3. 03AnimalOther designEfficacy outcome

    In a systematic review of animal and human models, semaglutide treatment decreased microbial diversity; the native result was not separated by animal/human model and its comparator and analyzed N were unstated.

    In plain wordsIn animal and human research reviewed together, semaglutide decreased gut microbial diversity; the specific model and comparison were unstated.

    Peptide
    Semaglutide
    Outcome
    DecreaseGut microbial diversity
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, varied results were obtained after semaglutide treatment, in which A. muciniphila, known for its positive metabolic functions, increased; however, microbial diversity decreased.
    2 context sentences
    Summary · context
    Our systematic review (based on PRISMA guidelines) aimed to gather knowledge on the effects of GLP-1 analogue medications on the composition, richness, and abundance of gut microbiota in both animal and human models.
    Summary · context
    Thirty-eight studies were included in this systematic review.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.